Cargando…
Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the COVID-19 pandemic, responsible for millions of deaths globally. Even with effective vaccines, SARS-CoV-2 will likely maintain a hold in the human population through gaps in efficacy, percent vaccinated, and arising new...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384068/ https://www.ncbi.nlm.nih.gov/pubmed/34124934 http://dx.doi.org/10.1128/MCB.00185-21 |
_version_ | 1783741846793486336 |
---|---|
author | van de Leemput, Joyce Han, Zhe |
author_facet | van de Leemput, Joyce Han, Zhe |
author_sort | van de Leemput, Joyce |
collection | PubMed |
description | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the COVID-19 pandemic, responsible for millions of deaths globally. Even with effective vaccines, SARS-CoV-2 will likely maintain a hold in the human population through gaps in efficacy, percent vaccinated, and arising new strains. Therefore, understanding how SARS-CoV-2 causes widespread tissue damage and the development of targeted pharmacological treatments will be critical in fighting this virus and preparing for future outbreaks. Herein, we summarize the progress made thus far by using in vitro or in vivo models to investigate individual SARS-CoV-2 proteins and their pathogenic mechanisms. We have grouped the SARS-CoV-2 proteins into three categories: host entry, self-acting, and host interacting. This review focuses on the self-acting and host-interacting SARS-CoV-2 proteins and summarizes current knowledge on how these proteins promote virus replication and disrupt host systems, as well as drugs that target the virus and virus interacting host proteins. Encouragingly, many of these drugs are currently in clinical trials for the treatment of COVID-19. Future coronavirus outbreaks will most likely be caused by new virus strains that evade vaccine protection through mutations in entry proteins. Therefore, study of individual self-acting and host-interacting SARS-CoV-2 proteins for targeted therapeutic interventions is not only essential for fighting COVID-19 but also valuable against future coronavirus outbreaks. |
format | Online Article Text |
id | pubmed-8384068 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-83840682021-09-03 Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19 van de Leemput, Joyce Han, Zhe Mol Cell Biol Minireview Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the COVID-19 pandemic, responsible for millions of deaths globally. Even with effective vaccines, SARS-CoV-2 will likely maintain a hold in the human population through gaps in efficacy, percent vaccinated, and arising new strains. Therefore, understanding how SARS-CoV-2 causes widespread tissue damage and the development of targeted pharmacological treatments will be critical in fighting this virus and preparing for future outbreaks. Herein, we summarize the progress made thus far by using in vitro or in vivo models to investigate individual SARS-CoV-2 proteins and their pathogenic mechanisms. We have grouped the SARS-CoV-2 proteins into three categories: host entry, self-acting, and host interacting. This review focuses on the self-acting and host-interacting SARS-CoV-2 proteins and summarizes current knowledge on how these proteins promote virus replication and disrupt host systems, as well as drugs that target the virus and virus interacting host proteins. Encouragingly, many of these drugs are currently in clinical trials for the treatment of COVID-19. Future coronavirus outbreaks will most likely be caused by new virus strains that evade vaccine protection through mutations in entry proteins. Therefore, study of individual self-acting and host-interacting SARS-CoV-2 proteins for targeted therapeutic interventions is not only essential for fighting COVID-19 but also valuable against future coronavirus outbreaks. American Society for Microbiology 2021-08-24 /pmc/articles/PMC8384068/ /pubmed/34124934 http://dx.doi.org/10.1128/MCB.00185-21 Text en Copyright © 2021 American Society for Microbiology. https://doi.org/10.1128/ASMCopyrightv2All Rights Reserved (https://doi.org/10.1128/ASMCopyrightv2) . https://doi.org/10.1128/ASMCopyrightv2This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Minireview van de Leemput, Joyce Han, Zhe Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19 |
title | Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19 |
title_full | Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19 |
title_fullStr | Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19 |
title_full_unstemmed | Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19 |
title_short | Understanding Individual SARS-CoV-2 Proteins for Targeted Drug Development against COVID-19 |
title_sort | understanding individual sars-cov-2 proteins for targeted drug development against covid-19 |
topic | Minireview |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8384068/ https://www.ncbi.nlm.nih.gov/pubmed/34124934 http://dx.doi.org/10.1128/MCB.00185-21 |
work_keys_str_mv | AT vandeleemputjoyce understandingindividualsarscov2proteinsfortargeteddrugdevelopmentagainstcovid19 AT hanzhe understandingindividualsarscov2proteinsfortargeteddrugdevelopmentagainstcovid19 |